Metformin is associated with reduced COVID-19 severity in patients with prediabetes

Simple item page
dc.contributor.authorChan, Lauren E.en
dc.contributor.authorCasiraghi, Elenaen
dc.contributor.authorLaraway, Bryanen
dc.contributor.authorColeman, Benen
dc.contributor.authorBlau, Hannahen
dc.contributor.authorZaman, Adninen
dc.contributor.authorHarris, Nomi L.en
dc.contributor.authorWilkins, Kennethen
dc.contributor.authorAntony, Blessyen
dc.contributor.authorGargano, Michaelen
dc.contributor.authorValentini, Giorgioen
dc.contributor.authorSahner, Daviden
dc.contributor.authorHaendel, Melissaen
dc.contributor.authorRobinson, Peter N.en
dc.contributor.authorBramante, Carolynen
dc.contributor.authorReese, Justinen
dc.date.accessioned2023-04-17T15:05:49Zen
dc.date.available2023-04-17T15:05:49Zen
dc.date.issued2022-12en
dc.description.abstractAims: Studies suggest that metformin is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemics. We assessed if metformin is associated with reduced incidence of severe COVID-19 for patients with prediabetes or polycystic ovary syndrome (PCOS), common diseases that increase the risk of severe COVID-19. Methods: This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls). After balancing via inverse probability score weighting, associations with COVID-19 severity were assessed by logistic regression. Results: In the prediabetes cohort, when compared to levothyroxine, metformin was associated with a significantly lower incidence of COVID-19 with "mild-ED" or worse (OR [95% CI]: 0.636, [0.455-0.888]) and "moderate" or worse severity (0.493 [0.339-0.718]). Compared to ondansetron, metformin was associated with lower incidence of "mild-ED" or worse severity (0.039 [0.026-0.057]), "moderate" or worse (0.045 [0.03-0.069]), "severe" or worse (0.183 [0.077-0.431]), and "mortality/hospice" (0.223 [0.071-0.694]). For PCOS, metformin showed no significant differences in severity compared to levothyroxine, but was associated with a significantly lower incidence of "mild-ED" or worse (0.101 [0.061-0.166]), and "moderate" or worse (0.094 [0.049-0.18]) COVID-19 outcome compared to ondansetron. Conclusions: Metformin use is associated with less severe COVID-19 in patients with prediabetes or PCOS.en
dc.description.notesThe analyses described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave (covid.cd2h. org/enclave) and supported by CD2H -The National COVID Cohort Collaborative (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306, DUR: RP-7BE1AC. This research was possible because of the patients whose information is included within the data from participating organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas) who have contributed to the on-going development of this community resource 27 The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the N3C program.; The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol #IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources.en
dc.description.sponsorshipCD2H -The National COVID Cohort Collaborative (N3C) IDeA CTR Collaboration [3U24TR002306-04S2 NCATS U24 TR002306, DUR: RP-7BE1AC]en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1016/j.diabres.2022.110157en
dc.identifier.eissn1872-8227en
dc.identifier.other110157en
dc.identifier.pmid36400170en
dc.identifier.urihttp://hdl.handle.net/10919/114523en
dc.identifier.volume194en
dc.language.isoenen
dc.publisherElsevieren
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectMetforminen
dc.subjectPolycystic ovary syndromeen
dc.subjectPrediabetesen
dc.subjectGlycemiaen
dc.subjectCOVID-19en
dc.titleMetformin is associated with reduced COVID-19 severity in patients with prediabetesen
dc.title.serialDiabetes Research and Clinical Practiceen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S0168822722009718-main.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Scholarly Works, Computer Science